Elevance Health Inc. (ELV), a large-cap growth insurer, has received a 91% rating from Validea's P/E/Growth Investor model, based on Peter Lynch's strategy. This strong endorsement indicates ELV meets criteria for reasonable valuation relative to earnings growth and a solid balance sheet, positioning it as a potentially compelling investment opportunity for investors seeking growth at a reasonable price.
Elevance Health Inc. (ELV) has received a strong endorsement from Validea's P/E/Growth Investor model, scoring 91% based on the strategy of Peter Lynch. This high rating indicates a strong interest from the model, which favors companies exhibiting growth at a reasonable price (GARP) coupled with a robust financial position. The analysis reveals that ELV successfully passed key criteria including its Yield Adjusted P/E to Growth (PEG) Ratio, Earnings Per Share (EPS) growth, Equity/Assets Ratio, and Return on Assets (ROA), signaling strength in valuation, profitability, and asset efficiency. However, the model returned a neutral rating for the company's Total Debt/Equity Ratio, Free Cash Flow, and Net Cash Position. This suggests that while core growth and profitability metrics are compelling, aspects of its balance sheet and cash generation, while not concerning, are not standout strengths according to this specific screen.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
